Business Wire

OH-GE-AEROSPACE

19.6.2024 08:01:30 CEST | Business Wire | Press release

Share
GE Aerospace Announces Voluntary Delisting of GE Common Stock from Euronext Paris, the London Stock Exchange and the SIX Swiss Exchange

GE AEROSPACE (GENERAL ELECTRIC COMPANY; NYSE: GE) announced today that, as part of a simplification project following the launch of GE Aerospace as an independent public company, it has submitted applications for the delisting of GE common stock (ISIN Code US3696043013) from Euronext Paris, the London Stock Exchange and the SIX Swiss Exchange (the “Delisting”). This action follows a comprehensive review of the trading volume, cost and administrative requirements related to these listings. Following the Delisting, GE Aerospace shares will continue to be traded on the New York Stock Exchange (“NYSE”), GE Aerospace’s primary listing exchange.

The following required information is provided in connection with the Delisting from Euronext Paris. The Delisting has been approved by the Listing Board of Euronext Paris S.A.

Information Regarding Delisting Procedure for Euronext Paris

A sales facility procedure (the “Sales Facility”) will be put in place from 21 June 2024 to 19 July 2024 (the “Sales Facility Period”) to allow shareholders to sell on the NYSE their GE Aerospace shares which are listed on Euronext Paris and held in the Euroclear France clearing system (the “GE Aerospace Euronext Shares”). GE Aerospace has appointed Uptevia to act as centralizing agent under the Sales Facility (the “Centralizing Agent”).

During the Sales Facility Period, shareholders with GE Aerospace Euronext Shares will have the following options:

  • sell on a voluntary basis all or part of their GE Aerospace Euronext Shares on the NYSE by participating in the Sales Facility (described in more detail below); or
  • retain all or part of their GE Aerospace Euronext Shares, which will continue to be traded on Euronext Paris during the entire Sales Facility Period until and including the trading day prior to the date of the Delisting.

The GE Aerospace Euronext Shares will be delisted from Euronext Paris on 25 July 2024 (the “Delisting Date”).

Shareholders not participating

Shareholders who do not wish to sell their GE Aerospace Euronext Shares under the Sales Facility or directly on Euronext Paris, or have otherwise taken no action by the Delisting Date, will be able to trade their GE Aerospace Euronext Shares on the NYSE, subject to the terms and conditions applied by their financial intermediaries.

Participating shareholders

Shareholders who wish to sell their GE Aerospace Euronext Shares on the NYSE under the Sales Facility should request their financial intermediaries to deliver their GE Aerospace Euronext Shares during the Sales Facility Period to the Centralizing Agent, pursuant to the procedure described below.

The GE Aerospace Euronext Shares delivered to the Centralizing Agent during the Sales Facility Period will be sold on the NYSE as from 26 July 2024 by a broker, at market prices prevailing at the time of the sale. The Centralizing Agent will calculate the average sale price of the GE Aerospace Euronext Shares and will be in charge of transferring the sale proceeds (which will be converted into euros from U.S. dollars by Uptevia) to the GE Aerospace shareholders participating in the Sales Facility once it has received the funds for the sale of all of the GE Aerospace Euronext Shares tendered under the Sales Facility.

GE Aerospace will pay the brokerage commissions on the NYSE for the sale of GE Aerospace Euronext Shares tendered pursuant to the Sales Facility, the fee of the Centralizing Agent and any applicable foreign exchange commission that would be incurred in connection with the Sales Facility.

The Sales Facility procedure is also described in a Euronext notice to be published on 19 June 2024.

No guarantee can be given by GE Aerospace or by the Centralizing Agent as to the price at which the GE Aerospace Euronext Shares tendered pursuant to the Sales Facility will be sold. The Sales Facility is being provided solely as an accommodation to holders of GE Aerospace Euronext Shares. Holders (and in particular individual investors) of GE Aerospace Euronext Shares may decide not to participate in the Sales Facility or may decide not to take any action, in which case no guarantee can be given on the terms, including costs, that would be applied by their financial intermediary after the Delisting. Individual investors are urged to consult their own investment advisors before deciding to participate or not in this process.

The contemplated timetable of the Sales Facility and the Delisting can be summarized as follows (it being specified that GE Aerospace reserves the right to amend this calendar):

Event

Date

Sales Facility

Beginning of the Sales Facility

21 June 2024

End of the Sales Facility

19 July 2024

End of the centralization by Uptevia

23 July 2024

Sale on the NYSE of the GE Aerospace Euronext Shares tendered in the Sales Facility

As from 26 July 2024

Settlement of the proceeds of the Sales Facility to the relevant financial intermediary

As soon as possible after receipt of the proceeds of the Sales Facility

Delisting

Last day of trading of GE Aerospace Euronext Shares on Euronext Paris

24 July 2024

Delisting of GE Aerospace Euronext Shares on Euronext Paris

25 July 2024

GE Aerospace shareholders participating in the Sales Facility are reminded that they acknowledge and accept (i) the risk implied from the change in the share market price and/or applicable exchange rates between the date on which their shares are delivered to Uptevia for participation in the Sales Facility and the receipt of the applicable average sale proceeds, and (ii) that from the time the GE Aerospace Euronext Shares are delivered to Uptevia, they will not be entitled to any subsequent dividend declared by GE Aerospace. They are also reminded that any orders to tender GE Aerospace Euronext Shares to the Sales Facility are irrevocable, as is the subsequent sale of such GE Aerospace Euronext Shares tendered on the NYSE.

Shareholders may request any additional information from their custodian and usual financial intermediary, who has received the details of the Delisting.

About GE AEROSPACE

GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 44,000 commercial and 26,000 military aircraft engines. With a global team of 52,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow and the future at www.geaerospace.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240618573691/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye